Literature DB >> 3652057

Limited sampling model for vinblastine pharmacokinetics.

M J Ratain1, N J Vogelzang.   

Abstract

A limited sampling model was developed for vinblastine to estimate the total area under the concentration time curve (AUC) using only two timepoints. Detailed pharmacokinetic analysis (16 timepoints) was performed in 30 patients treated with a small bolus dose (3 mg/m2) of vinblastine. A model for the total AUC was developed by multiple linear regression, using the first 15 patients as the training data set: AUC = 38.0 C10 + 73.8 C36 - 12.9, where C10 and C36 represent the serum vinblastine concentration at 10 hours and 36 hours, respectively (r = 0.99, P less than 0.0001). The model was validated on the other 15 patients, the test data set (r = 0.94, P less than 0.0001), with a mean predictive error of 13%. Limited sampling models may facilitate large-scale pharmacodynamic studies of new anticancer drugs, in order to relate the estimated AUC to toxicity and/or response without the need for detailed pharmacokinetic analysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3652057

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  15 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  A limited sampling method for estimation of the etoposide area under the curve.

Authors:  A S Strömgren; B T Sørensen; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Limited sampling strategy for determining metformin area under the plasma concentration-time curve.

Authors:  Ana Beatriz Santoro; Tore Bjerregaard Stage; Claudio José Struchiner; Mette Marie Hougaard Christensen; Kim Brosen; Guilherme Suarez-Kurtz
Journal:  Br J Clin Pharmacol       Date:  2016-07-24       Impact factor: 4.335

4.  Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam.

Authors:  Stephanie Katzenmaier; Christoph Markert; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2010-08-03       Impact factor: 2.953

5.  A limited sampling method for estimation of the carboplatin area under the curve.

Authors:  B T Sørensen; A Strömgren; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Limited-sampling models for anticancer agents.

Authors:  L J van Warmerdam; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  Development and validation of limited-sampling strategies for predicting amoxicillin pharmacokinetic and pharmacodynamic parameters.

Authors:  G Suarez-Kurtz; F M Ribeiro; F L Vicente; C J Struchiner
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.

Authors:  G G Chabot
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children.

Authors:  B U Mueller; L L Lewis; G J Yuen; M Farley; A Keller; J A Church; J C Goldsmith; D J Venzon; M Rubin; P A Pizzo; F M Balis
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  A limited sampling model for the pharmacokinetics of etoposide given orally.

Authors:  D Gentili; M Zucchetti; V Torri; C Sessa; J de Jong; F Cavalli; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.